In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) closed at $8.52 in the last session, down -0.70% from day before closing price of $8.58. In other words, the price has decreased by -$0.70 from its previous closing price. On the day, 1.41 million shares were traded. BCRX stock price reached its highest trading level at $8.675 during the session, while it also had its lowest trading level at $8.515.
Ratios:
We take a closer look at BCRX’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.86 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 115.39. For the most recent quarter (mrq), Quick Ratio is recorded 2.22 and its Current Ratio is at 2.25.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on April 29, 2025, initiated with a Overweight rating and assigned the stock a target price of $20. On February 25, 2025, Wedbush started tracking the stock assigning a Outperform rating and target price of $15.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 13 ’25 when HEGGIE THERESA sold 70,000 shares for $8.51 per share. The transaction valued at 595,868 led to the insider holds 65,352 shares of the business.
HEGGIE THERESA bought 70,000 shares of BCRX for $595,871 on Aug 13 ’25. On Dec 13 ’24, another insider, Hutson Nancy J, who serves as the Director of the company, sold 7,000 shares for $7.54 each. As a result, the insider received 52,780 and left with 86,638 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCRX now has a Market Capitalization of 1788518528 and an Enterprise Value of 2267400960. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.21. Its current Enterprise Value per Revenue stands at 4.067 whereas that against EBITDA is 38.754.
Stock Price History:
The Beta on a monthly basis for BCRX is 1.13, which has changed by -0.012746215 over the last 52 weeks, in comparison to a change of 0.1590569 over the same period for the S&P500. Over the past 52 weeks, BCRX has reached a high of $11.31, while it has fallen to a 52-week low of $6.01. The 50-Day Moving Average of the stock is -2.66%, while the 200-Day Moving Average is calculated to be 0.80%.
Shares Statistics:
According to the various share statistics, BCRX traded on average about 3.34M shares per day over the past 3-months and 2076180 shares per day over the past 10 days. A total of 209.91M shares are outstanding, with a floating share count of 202.70M. Insiders hold about 3.44% of the company’s shares, while institutions hold 93.95% stake in the company. Shares short for BCRX as of 1755216000 were 27082099 with a Short Ratio of 8.11, compared to 1752537600 on 26779523. Therefore, it implies a Short% of Shares Outstanding of 27082099 and a Short% of Float of 12.950000000000001.
Earnings Estimates
The performance of Biocryst Pharmaceuticals Inc (BCRX) in the stock market is under the watchful eye of 4.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is $0.03, with high estimates of $0.04 and low estimates of $0.02.
Analysts are recommending an EPS of between $0.36 and $0.06 for the fiscal current year, implying an average EPS of $0.15. EPS for the following year is $0.45, with 5.0 analysts recommending between $0.8 and $0.3.
Revenue Estimates
According to 9 analysts, the current quarter’s revenue is expected to be $162.24M. It ranges from a high estimate of $166.22M to a low estimate of $156M. As of the current estimate, Biocryst Pharmaceuticals Inc’s year-ago sales were $117.08MFor the next quarter, 9 analysts are estimating revenue of $155.74M. There is a high estimate of $162.08M for the next quarter, whereas the lowest estimate is $147.98M.
A total of 9 analysts have provided revenue estimates for BCRX’s current fiscal year. The highest revenue estimate was $631.12M, while the lowest revenue estimate was $611.65M, resulting in an average revenue estimate of $625.38M. In the same quarter a year ago, actual revenue was $450.71MBased on 9 analysts’ estimates, the company’s revenue will be $669.41M in the next fiscal year. The high estimate is $702M and the low estimate is $637.68M.
